Asundexian versus Apixaban in Patients with Atrial Fibrillation

Jonathan P. Piccini; Manesh R. Patel; Jan Steffel; Keith C. Ferdinand; Isabelle C. Van Gelder; Andrea M. Russo; Chang-Sheng Ma; Shaun G. Goodman; Jonas Oldgren; Christopher Hammett; Renato D. Lópes; Masaharu Akao; Raffaele De Caterina; Paulus Kirchhof; Diana A. Gorog; Martin E W Hemels; Michiel Rienstra; W. Schuyler Jones; Josephine Harrington; Professor Gregory Lip; Stephen J. Ellis; Frank W. Rockhold; Christoph Neumann; John H. Alexander; Thomas Viethen; James Hung; Rosa Coppolecchia; Hardi Mundl; Valeria Caso

doi:10.1056/nejmoa2407105

Abstract

1 min read

Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the period before the trial was stopped prematurely. There were fewer major bleeding events with asundexian than with apixaban during this time. (Funded by Bayer; OCEANIC-AF ClinicalTrials.gov number, NCT05643573; EudraCT number, 2022-000758-28.).

Related publications

Article2020

Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

Ken Okumura, Masaharu Akao, Tetsuro Yoshida, Masahito Kawata, Osamu Okazaki, Shintaro Akashi, Kenichi Eshima, Kimihiko Tanizawa, M. Fukuzawa, Takuya Hayashi, Masahiro Akishita, Professor Gregory Lip, Takeshi Yamashita

Article2019

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention

Jakub Gumprecht, Magdalena Domek, Professor Gregory Lip

Article2025

Plain language summary of the direct oral anticoagulant switch study: effect of switching or continuing apixaban or rivaroxaban among people with non-valvular atrial fibrillation

Steven Deitelzweig, Jenny Jiang, Dong Cheng, Professor Gregory Lip

Article2016

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

C. Michael Gibson, Roxana Mehran, Christoph Bode, Jonathan L. Halperin, Freek W.A. Verheugt, Peter Wildgoose, Mary C. Birmingham, Juliana Ianus, Paul Burton, Martin van Eickels, Serge Korjian, Yazan Daaboul, Professor Gregory Lip, Marc Cohen, Steen Husted, Eric D. Peterson, Keith A.A. Fox

Article2017

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice

Xiaoyan Li, Steve Deitelzweig, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Professor Gregory Lip